Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2012-03-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Panel 1: BMS-823778 or Placebo matching BMS-823778
Healthy Subjects
BMS-823778
Capsules, Oral, 2 mg, Once daily, 14 days
Placebo matching with BMS-823778
Capsules, Oral, 0 mg, Once daily, 14 days
Panel 2: BMS-823778 or Placebo matching BMS-823778
Healthy Subjects
BMS-823778
Capsules, Oral, 12 mg, Once daily, 14 days
Placebo matching with BMS-823778
Capsules, Oral, 0 mg, Once daily, 14 days
Panel 3: BMS-823778 or Placebo matching BMS-823778
Healthy Subjects
BMS-823778
Capsules, Oral, 25 mg, Once daily, 14 days
Placebo matching with BMS-823778
Capsules, Oral, 0 mg, Once daily, 14 days
Panel 4: BMS-823778 or Placebo matching BMS-823778
Subjects with T2DM
BMS-823778
Capsules, Oral, 2 mg, Once daily, 14 days
Placebo matching with BMS-823778
Capsules, Oral, 0 mg, Once daily, 14 days
Panel 5: BMS-823778 or Placebo matching BMS-823778
Subjects with T2DM
BMS-823778
Capsules, Oral, 15 mg, Once daily, 14 days
Placebo matching with BMS-823778
Capsules, Oral, 0 mg, Once daily, 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-823778
Capsules, Oral, 2 mg, Once daily, 14 days
BMS-823778
Capsules, Oral, 12 mg, Once daily, 14 days
BMS-823778
Capsules, Oral, 25 mg, Once daily, 14 days
BMS-823778
Capsules, Oral, 15 mg, Once daily, 14 days
Placebo matching with BMS-823778
Capsules, Oral, 0 mg, Once daily, 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Symptoms of poorly controlled diabetes that would preclude participation in this placebo-controlled trial
* Insulin therapy within one year of screening
20 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Hachioji-Shi, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Investigator Inquiry form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MB121-009
Identifier Type: -
Identifier Source: org_study_id